Skip to main content
European Commission logo print header

Targeting the purinergic system for disease-modification in epilepsy

Description du projet

De nouvelles cibles thérapeutiques dans l’épilepsie

L’épilepsie est une maladie neurologique qui se caractérise par des crises d’épilepsie. Les thérapies actuelles sont inefficaces chez près de 30 % des patients, ce qui nécessite le développement de nouveaux traitements. Le projet EpiPurines, financé par l’UE, se concentre sur le système de signalisation purinergique, qui est activé par les nucléotides et les nucléosides. À l’aide de modèles animaux malades et de cellules souches pluripotentes induites, les scientifiques étudieront les résultats du ciblage de divers récepteurs et enzymes impliqués dans les voies de signalisation de ce système. Les résultats nous aideront à comprendre le rôle de la signalisation purinergique dans l’épileptogenèse et ouvriront la voie à de nouveaux médicaments permettant de mieux contrôler les crises et de supprimer l’épilepsie.

Objectif

Current epilepsy therapies, based on mediating excitation or inhibition, are ineffective in 30% of patients & have no impact on disease progression, demonstrating an urgent need for new therapies. Mounting evidence showed the therapeutic potential of targeting the purinergic system during epilepsy with the disease-modifying effects observed via targeting the P2X7 receptor & Adenosine kinase (ADK) being a promise. P2X7 & ADK are increased in the brain in experimental models of epilepsy and in patient brain. Further, data showed anticonvulsive & anti-epileptogenic potential of targeting P2X7 or ADK. To advance these findings towards a clinical application, results must be replicated in animal models mimicking closer the human condition (e.g.TBI model) and effects must be tested in human cells (hiPSC). Importantly, while there is now compelling evidence demonstrating the therapeutic potential of targeting both P2X7 & ADK separately, a combined treatment, targeting both simultaneously, may lead to better seizure control & suppression of epilepsy. By using relevant animal models of epilepsy and hiPSC, EpiPurines will establish the disease-modifying potential of targeting different components of the purinergic system during epileptogenesis, thereby establishing P2X7 & ADK-targeting as potential treatment for epilepsy. To achieve this, EpiPurines brings together, for the first time, a team of experts in purinergic signaling from different research fields (Adenosine & ATP-signalling) & industrial partners. This highly interdisciplinary & intersectoral approach will contribute significantly to the understanding of purinergic signalling during seizures & epilepsy providing novel therapeutic approaches. The skills acquired during the research project, the excellent training record of the supervisors & host institutions and the outstanding resources for learning & development available at RCSI & RU will give me the tools necessary to become a highly employable neuroscientist.

Régime de financement

MSCA-IF-GF - Global Fellowships

Coordinateur

ROYAL COLLEGE OF SURGEONS IN IRELAND
Contribution nette de l'UE
€ 257 561,28
Adresse
ST STEPHEN'S GREEN 123
2 Dublin
Irlande

Voir sur la carte

Région
Ireland Northern and Western Border
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 257 561,28

Partenaires (1)